Achieving Data Quality and Integrity in Maximum Containment Laboratories
Virtual course - June 14-18, 2021 Registration is open. Apply to attend by May 14, 2021. There is no cost to attend, but seating is limited, and pre-registration is required. Note that course attendees are invited based upon diversity of roles, responsibilities, and organization. Interested participants will be placed on a waitlist once seats are filled. Background FDA helps protect the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats by ensuring that medical countermeasures (MCMs—for example, drugs, vaccines, and diagnostic tests) to counter these threats are safe, effective, and secure. Scientists working to develop MCMs against several high-priority biological threat agents are at high risk of aerosol-transmitted laboratory infection and life-threatening disease, as there are no vaccines or treatments for these agents. Accordingly, much of the work to develop MCMs for these high-priority agents must be done in high and maximum biosafety level (BSL)-4 laboratories to prevent the agents from being released into the environment, and to provide maximum safety for the scientists.